News & Updates

In the 52-week open-label extension (OLE) of a phase IIb study presented at AAAAI 2023, the BTK* inhibitor remibrutinib demonstrated sustained efficacy and a favourable safety profile for the treatment of chronic spontaneous urticaria (CSU).

Treatment with phosphodiesterase 5 inhibitors (PDE5i) may provide survival benefits to patients with interstitial lung disease (ILD)-related pulmonary hypertension (PH), particularly in those with severe disease and normal baseline right ventricular (RV) dysfunction, suggest the results of a retrospective observational cohort study.

A recent study has provided further evidence on the incidence of central nervous system (CNS) coccidioidomycosis, which is a rare and potentially dangerous complication of disseminated coccidioidomycosis. Many patients present with relatively low compliment fixation (CF) titer, and hydrocephalus often occurs.

For children with uncomplicated malaria, early treatment with an ultra-short course of high-dose primaquine is noninferior to delayed treatment at preventing Plasmodium vivax infection, according to a study.

New drug applications approved by US FDA as of 01-15 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.